ClinicalTrials.gg
CompletedNCT01225211Updated Oct 5, 2015Results posted

Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation

A Phase 2 interventional study of Lumacaftor and Ivacaftor in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 56 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-10-05.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
312
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing lumacaftor in Cystic Fibrosis — none open to participants now, none under way, none of them phase 3. lumacaftor · Cystic Fibrosis.

Enrollment
4th of 20
312 · median 66
Started
2010
with 1 other
Phase 2
4 of 20
none open now
Registered
4th of 20
by date
Lead sponsor
20 of 20
Vertex Pharmaceuticals Incorporated

Among the 20 studies testing lumacaftor in Cystic Fibrosis, this one is the 4th largest by enrollment, is one of 2 that started in 2010, is one of 4 in phase 2, and was the 4th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

None of the 20 studies testing lumacaftor in Cystic Fibrosis is open now. The open studies under Cystic Fibrosis, anywhere →

About lumacaftor

lumacaftor: first FDA approval 2015 (ORKAMBI), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies testing lumacaftor in Cystic Fibrosis as a file.
02

Study summary

The purpose of this study is to evaluate of the safety, efficacy, pharmacokinetics (PK) and pharmacodynamic (PD) effects of lumacaftor (VX-809) alone and when coadministered with ivacaftor (VX-770) in participants with cystic fibrosis, homozygous or heterozygous for the F508del-CFTR mutation.

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants with confirmed diagnosis of CF
  • Must have the F508del-CFTR mutation on at least 1 allele.
  • greater than equal (>=) 40% of predicted normal for age, gender, and height (Knudson standards)(Cohort 1, 2, and 3); FEV1 40-90% of predicted normal for age, gender, and height (Hankinson standards (Cohort 4)
  • Participant of and who are sexually active must meet the requirements

Exclusion criteria

Exclusion Criteria:

  • History of any illness or condition that, in the opinion of the investigator might confound the results of the study or pose an additional risk in administering study drug to the participant (e.g., cirrhosis with portal hypertension).
  • An acute illness including acute upper or lower respiratory infection, pulmonary exacerbation or changes in therapy (including antibiotics) for pulmonary disease within 14 days (Cohort 1, 2, and 3) or 28 days (Cohort 4) before receiving the first dose of study drug.
  • History of solid organ or hematological transplantation.
  • History of alcohol abuse or drug addiction in the past year, including cannabis, cocaine, and opiates.
  • Ongoing participation in another therapeutic clinical study, or prior participation in an drug study without appropriate
  • Pregnant or nursing females; females of who are unwilling or unable to use an acceptable method of non-hormonal
  • Participants enrolled in Cohort 1 or Cohort 2 will not be eligible for Cohort 3
  • Ongoing or prior participation in an investigational drug study within 30 days of the Screening Visit
  • Heterozygous participants who participated in Cohort 2 and meet the eligibility criteria for Cohort 4 may participate in Cohort 4
  • Evidence of lens opacity or cataract as determined by the ophthalmologic examination (Cohort 4 only)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
312 participants (actual)

Study arms

  • Placebo comparator
    Cohort 1: Placebo

    Participants homozygous (HO) for the F508del-CF transmembrane conductance regulator gene (CFTR) mutation received lumacaftor matched placebo once daily (qd) (Day 1 through Day 14), followed by lumacaftor matched placebo qd in combination with ivacaftor matched placebo every 12 hours (q12h) (Day 15 through Day 21).

    Drug: Lumacaftor Placebo · Drug: Ivacaftor Placebo

  • Experimental
    Cohort 1: LUM 200 mg qd/LUM 200 mg qd+IVA 150 mg q12h

    Participants homozygous for the F508del-CFTR mutation received 200 milligram (mg) of lumacaftor (LUM) qd (Day 1 through Day 14), followed by 200 mg of lumacaftor qd in combination with 150 mg of ivacaftor (IVA) q12h (Day 15 through Day 21).

    Drug: Lumacaftor · Drug: Ivacaftor

  • Experimental
    Cohort 1: LUM 200 mg qd/LUM 200 mg qd+IVA 250 mg q12h

    Participants homozygous for the F508del-CFTR mutation received 200 mg of lumacaftor alone qd (Day 1 through Day 14), followed by 200 mg of lumacaftor qd in combination with 250 mg of ivacaftor q12h (Day 15 through Day 21).

    Drug: Lumacaftor · Drug: Ivacaftor

  • Placebo comparator
    Cohort 2 and 3: Placebo (HO and HE)

    Participants homozygous or heterozygous for the F508del-CFTR mutation received lumacaftor matched placebo qd (Day 1 through Day 28), followed by lumacaftor matched placebo in combination with ivacaftor matched placebo q12h (Day 29 through Day 56).

    Drug: Lumacaftor Placebo · Drug: Ivacaftor Placebo

  • Experimental
    Cohort 2: LUM 200 mg qd/LUM 200 mg qd+IVA 250 mg q12h (HO)

    Participants homozygous for the F508del-CFTR mutation received 200 mg of lumacaftor alone qd (Day 1 through Day 28), followed by 200 mg of lumacaftor qd in combination with 250 mg of ivacaftor q12h (Day 29 through Day 56).

    Drug: Lumacaftor · Drug: Ivacaftor

  • Experimental
    Cohort 2: LUM 400 mg qd/LUM 400 mg qd+IVA 250 mg q12h (HO)

    Participants homozygous for the F508del-CFTR mutation received 400 mg of lumacaftor alone qd (Day 1 through Day 28), followed by 400 mg of lumacaftor qd in combination with 250 mg of ivacaftor q12h (Day 29 through Day 56).

    Drug: Lumacaftor · Drug: Ivacaftor

  • Experimental
    Cohort 2: LUM 600 mg qd/LUM 600 mg qd+IVA 250 mg q12h (HO&HE)

    Participants homozygous or heterozygous for the F508del-CFTR mutation received 600 mg of lumacaftor alone qd (Day 1 through Day 28), followed by 600 mg of lumacaftor qd in combination with 250 mg of ivacaftor q12h (Day 29 through Day 56).

    Drug: Lumacaftor · Drug: Ivacaftor

  • Experimental
    Cohort 3: LUM 400 mg q12h/LUM 400 mg q12h+IVA 250 mg q12h (HO)

    Participants homozygous for the F508del-CFTR mutation received 400 mg of lumacaftor alone q12h (Day 1 through Day 28), followed by 400 mg of lumacaftor q12h in combination with 250 mg of ivacaftor q12h (Day 29 through Day 56).

    Drug: Lumacaftor · Drug: Ivacaftor

  • Placebo comparator
    Cohort 4: Placebo

    Participants heterozygous for the F508del-CFTR mutation received lumacaftor matched placebo in combination with ivacaftor matched placebo q12h (Day 1 through Day 56).

    Drug: Lumacaftor Placebo · Drug: Ivacaftor Placebo

  • Experimental
    Cohort 4: LUM 400 mg q12h+IVA 250 mg q12h

    Participants heterozygous for the F508del-CFTR mutation received 400 mg of lumacaftor q12h in combination with 250 mg of ivacaftor q12h (Day 1 through Day 56).

    Drug: Lumacaftor · Drug: Ivacaftor

Interventions

  • Tablet

    Also known as: VX-809, LUM

  • Tablet.

    Also known as: VX-770, IVA

  • DrugLumacaftor Placebo

    Matching placebo tablet.

  • DrugIvacaftor Placebo

    Matching placebo tablet.

06

What researchers measure

Primary outcomes

  1. Cohort 1: Safety and Tolerability Based on Adverse Events (AEs)

    AE: any untoward medical occurrence in a participant during study; irrespective of relationship with treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after informed consent. AE includes serious AEs (SAEs) as well as Non-SAEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. Number of participants with AEs and SAEs are reported. AE that started at/after initial dosing of study drug, or increased in severity after initial dosing of study drug is considered treatment-emergent. Results are reported separately for monotherapy period (Period 1: Day 1 to Day 14) and combination therapy period (Period 2: Day 15 to Day 21).

    Time frame: Cohort 1: Day 1 up to 28 days after last dose (Last dose = Day 21)

  2. Cohort 2 and 3: Safety and Tolerability Based on Adverse Events (AEs)

    Detailed description is provided in Outcome Measure 1. Results are reported separately for monotherapy period (Period 1: Day 1 to Day 28) and combination therapy period (Period 2: Day 29 to Day 56).

    Time frame: Cohort 2 and 3: Day 1 up to 28 days after last dose (Last dose = Day 56)

  3. Cohort 4: Safety and Tolerability Assessed by Number of Participants With AEs and SAEs

    AEs and SAEs are defined in Outcome Measure 1.

    Time frame: Cohort 4: Day 1 up to 28 days after last dose (Last dose = Day 56)

  4. Cohort 1: Absolute Change From Day 14 in Sweat Chloride at Day 21

    Time frame: Cohort 1: Day 14, Day 21

  5. Cohort 2 And 3: Absolute Change From Day 28 in Sweat Chloride at Day 56

    Time frame: Cohort 2 and 3: Day 28, Day 56

  6. Cohort 4: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Day 56

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. ppFEV1 (predicted for age, gender, and height) was calculated using the Hankinson method.

    Time frame: Cohort 4: Baseline, Day 56

Secondary outcomes

  1. Cohort 1: Absolute Change From Baseline in Sweat Chloride at Day 14

    Time frame: Cohort 1: Baseline, Day 14

  2. Cohort 2 And 3: Absolute Change From Baseline in Sweat Chloride at Day 14

    Time frame: Cohort 2: Baseline, Day 14

  3. Cohort 4: Absolute Change From Baseline in Sweat Chloride at Day 56

    Time frame: Cohort 4: Baseline, Day 56

  4. Cohort 1: Absolute Change From Day 14 in FEV1 at Day 21

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

    Time frame: Cohort 1: Day 14, Day 21

  5. Cohort 1: Absolute Change From Day 14 in ppFEV1 at Day 21

    FEV1 and ppFEV1 are defined in Outcome Measure 6.

    Time frame: Cohort 1: Day 14, Day 21

  6. Cohort 2 and 3: Absolute Change From Day 28 in ppFEV1 at Day 56

    FEV1 and ppFEV1 are defined in Outcome Measure 6.

    Time frame: Cohort 2 and 3: Day 28, Day 56

  7. Cohort 2 and 3: Relative Change From Day 28 in ppFEV1 at Day 56

    FEV1 and ppFEV1 are defined in Outcome Measure 6.

    Time frame: Cohort 2 and 3: Day 28, Day 56

  8. Cohort 2 and 3: Absolute Change From Baseline in ppFEV1 at Day 28 and 56

    FEV1 and ppFEV1 are defined in Outcome Measure 6.

    Time frame: Cohort 2 and 3: Baseline, Day 28 and 56

  9. Cohort 2 and 3: Relative Change From Baseline in FEV1 at Day 28 and 56

    FEV1 and ppFEV1 are defined in Outcome Measure 6.

    Time frame: Cohort 2 and 3: Baseline, Day 28 and 56

  10. Cohort 4: Relative Change From Baseline in Percent Predicted FEV1 at Day 56

    FEV1 and ppFEV1 are defined in Outcome Measure 6.

    Time frame: Cohort 4: Baseline, Day 56

  11. Cohort 2 and 3: Absolute Change From Day 28 in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score at Day 56

    The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for subjects with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.

    Time frame: Cohort 2 and 3: Day 28, Day 56

  12. Cohort 4: Absolute Change From Baseline in CFQ-R Respiratory Domain Score at Day 56

    CFQ-R respiratory domain is defined in Outcome Measure 17.

    Time frame: Cohort 4: Baseline, Day 56

  13. Cohort 4: Absolute Change From Baseline in Body Mass Index (BMI) at Day 56

    BMI was defined as weight in kilogram (kg) divided by height\*height in square meter (m\^2).

    Time frame: Cohort 4: Baseline, Day 56

  14. Cohort 4: Absolute Change From Baseline in Weight at Day 56

    Time frame: Cohort 4: Baseline, Day 56

07

Results

Posted Oct 5, 2015

Participant flow

Participants in each cohort are mutually exclusive. A total of 312 participants were randomized of which one participant did not receive any treatment and a total of 311 participants were treated.

Participant flow — Overall Study
MilestoneCohort 1: PlaceboCohort 1: LUM 200 mg qd/LUM 200 mg qd+IVA 150 mg q12hCohort 1: LUM 200 mg qd/LUM 200 mg qd+IVA 250 mg q12hCohort 2 and 3: Placebo (HO and HE)Cohort 2: LUM 200 mg qd/LUM 200 mg qd+IVA 250 mg q12h (HO)Cohort 2: LUM 400 mg qd/LUM 400 mg qd+IVA 250 mg q12h (HO)Cohort 2: LUM 600 mg qd/LUM 600 mg qd+IVA 250 mg q12h (HO&HE)Cohort 3: LUM 400 mg q12h/LUM 400 mg q12h+IVA 250 mg q12h (HO)Cohort 4: PlaceboCohort 4: LUM 400 mg q12h+IVA 250 mg q12h
Started21202127232142116362
Completed21202027232141116257
Not completed0010001015
Withdrew: Adverse event0010000001
Withdrew: Withdrawal by subject0000001013
Withdrew: Other0000000001

Outcome measures

PrimaryCohort 1: Safety and Tolerability Based on Adverse Events (AEs)

AE: any untoward medical occurrence in a participant during study; irrespective of relationship with treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after informed consent. AE includes serious AEs (SAEs) as well as Non-SAEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. Number of participants with AEs and SAEs are reported. AE that started at/after initial dosing of study drug, or increased in severity after initial dosing of study drug is considered treatment-emergent. Results are reported separately for monotherapy period (Period 1: Day 1 to Day 14) and combination therapy period (Period 2: Day 15 to Day 21).

Time frame:
Cohort 1: Day 1 up to 28 days after last dose (Last dose = Day 21)
Reported as:
Number · participants
Cohort 1: Safety and Tolerability Based on Adverse Events (AEs)
participantsCohort 1: Placebo - Period 1Cohort 1: LUM 200 mg qd - Period 1Cohort 1: Placebo - Period 2Cohort 1: LUM 200 mg qd+IVA 150 mg q12h - Period 2Cohort 1: LUM 200 mg qd+IVA 250 mg q12h - Period 2
Participants with any AEs1229151412
Participants with SAEs00000
PrimaryCohort 2 and 3: Safety and Tolerability Based on Adverse Events (AEs)

Detailed description is provided in Outcome Measure 1. Results are reported separately for monotherapy period (Period 1: Day 1 to Day 28) and combination therapy period (Period 2: Day 29 to Day 56).

Time frame:
Cohort 2 and 3: Day 1 up to 28 days after last dose (Last dose = Day 56)
Reported as:
Number · participants
Cohort 2 and 3: Safety and Tolerability Based on Adverse Events (AEs)
participantsCohort 2 and 3: Placebo (HO and HE) - Period 1Cohort 2: LUM 200 mg qd - Period 1Cohort 2: LUM 400 mg qd - Period 1Cohort 2: LUM 600 mg qd - Period 1Cohort 3: LUM 400 mg q12h - Period 1Cohort 2 and 3: Placebo (HO and HE) - Period 2Cohort 2: LUM 200 mg qd+IVA 250 mg q12h (HO) - Period 2Cohort 2: LUM 400 mg qd+IVA 250 mg q12h (HO) - Period 2Cohort 2: LUM 600 mg qd+IVA 250 mg q12h (HO&HE) - Period 2Cohort 3: LUM 400 mg q12h+IVA 250 mg q12h (HO) - Period 2
Participants with any AEs2318183772012152610
Participants with SAEs1203240141
PrimaryCohort 4: Safety and Tolerability Assessed by Number of Participants With AEs and SAEs

AEs and SAEs are defined in Outcome Measure 1.

Time frame:
Cohort 4: Day 1 up to 28 days after last dose (Last dose = Day 56)
Reported as:
Number · participants
Cohort 4: Safety and Tolerability Assessed by Number of Participants With AEs and SAEs
participantsCohort 4: PlaceboCohort 4: Active Study Drug
Participants with any AEs5352
Participants with SAEs59
PrimaryCohort 1: Absolute Change From Day 14 in Sweat Chloride at Day 21
Time frame:
Cohort 1: Day 14, Day 21
Reported as:
Least squares mean · millimole per liter (mmol/L)
Cohort 1: Absolute Change From Day 14 in Sweat Chloride at Day 21
millimole per liter (mmol/L)Cohort 1: LUM 200 mg qd+IVA 150 mg q12h - Period 2Cohort 1: LUM 200 mg qd+IVA 250 mg q12h - Period 2Cohort 1: Placebo - Period 2
Cohort 1: Absolute Change From Day 14 in Sweat Chloride at Day 21-2.131 (-5.381 to 1.119)-9.128 (-12.893 to -5.362)0.548 (-2.955 to 4.052)
Statistical analysis
  • Cohort 1: LUM 200 mg qd+IVA 150 mg q12h - Period 2 vs Cohort 1: Placebo - Period 2 · ANCOVA · p = 0.267 · Ls mean difference: -2.679 · 95% CI -7.484 to 2.125
  • Cohort 1: LUM 200 mg qd+IVA 250 mg q12h - Period 2 vs Cohort 1: Placebo - Period 2 · ANCOVA · p = <0.001 · Ls mean difference: -9.676 · 95% CI -14.801 to -4.551
PrimaryCohort 2 And 3: Absolute Change From Day 28 in Sweat Chloride at Day 56
Time frame:
Cohort 2 and 3: Day 28, Day 56
Reported as:
Least squares mean · mmol/L
Cohort 2 And 3: Absolute Change From Day 28 in Sweat Chloride at Day 56
mmol/LCohort 2: LUM 200 mg qd+IVA 250 mg q12h (HO) - Period 2Cohort 2: LUM 400 mg qd+IVA 250 mg q12h (HO) - Period 2Cohort 2: LUM 600 mg qd+IVA 250 mg q12h (HO) - Period 2Cohort 2: LUM 600 mg qd+IVA 250 mg q12h (HE) - Period 2Cohort 3: LUM 400 mg q12h+IVA 250 mg q12h (HO) - Period 2Cohort 2 and 3: Placebo (HO and HE) - Period 2
Cohort 2 And 3: Absolute Change From Day 28 in Sweat Chloride at Day 560.321 (-4.208 to 4.849)-1.043 (-5.800 to 3.714)-2.900 (-7.542 to 1.743)-1.240 (-6.287 to 3.807)-2.154 (-9.177 to 4.870)1.627 (-2.661 to 5.915)
Statistical analysis
  • Cohort 2: LUM 200 mg qd+IVA 250 mg q12h (HO) - Period 2 vs Cohort 2 and 3: Placebo (HO and HE) - Period 2 · ANCOVA · p = 0.680 · Ls mean difference: -1.306 · 95% CI -7.565 to 4.953
  • Cohort 2: LUM 400 mg qd+IVA 250 mg q12h (HO) - Period 2 vs Cohort 2 and 3: Placebo (HO and HE) - Period 2 · ANCOVA · p = 0.409 · Ls mean difference: -2.670 · 95% CI -9.053 to 3.712
  • Cohort 2: LUM 600 mg qd+IVA 250 mg q12h (HO) - Period 2 vs Cohort 2 and 3: Placebo (HO and HE) - Period 2 · ANCOVA · p = 0.161 · Ls mean difference: -4.526 · 95% CI -10.888 to 1.835
  • Cohort 2: LUM 600 mg qd+IVA 250 mg q12h (HE) - Period 2 vs Cohort 2 and 3: Placebo (HO and HE) - Period 2 · ANCOVA · p = 0.396 · Ls mean difference: -2.867 · 95% CI -9.543 to 3.810
  • Cohort 3: LUM 400 mg q12h+IVA 250 mg q12h (HO) - Period 2 vs Cohort 2 and 3: Placebo (HO and HE) - Period 2 · ANCOVA · p = 0.365 · Ls mean difference: -3.780 · 95% CI -12.028 to 4.467
PrimaryCohort 4: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Day 56

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. ppFEV1 (predicted for age, gender, and height) was calculated using the Hankinson method.

Time frame:
Cohort 4: Baseline, Day 56
Reported as:
Least squares mean · percent predicted of FEV1
Cohort 4: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Day 56
percent predicted of FEV1Cohort 4: PlaceboCohort 4: LUM 400 mg q12h+IVA 250 mg q12h
Cohort 4: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Day 56-1.23 ± 0.801-0.62 ± 0.829
Statistical analysis
  • Cohort 4: Placebo vs Cohort 4: LUM 400 mg q12h+IVA 250 mg q12h · Mixed Model Repeated Measure (MMRM) · p = 0.5978 · Ls mean difference: 0.60 · 95% CI -1.66 to 2.86
SecondaryCohort 1: Absolute Change From Baseline in Sweat Chloride at Day 14
Time frame:
Cohort 1: Baseline, Day 14
Reported as:
Least squares mean · mmol/L
Cohort 1: Absolute Change From Baseline in Sweat Chloride at Day 14
mmol/LCohort 1: LUM 200 mg qd - Period 1Cohort 1: Placebo - Period 1
Cohort 1: Absolute Change From Baseline in Sweat Chloride at Day 14-4.442 (-7.141 to -1.742)-1.668 (-5.606 to 2.271)
SecondaryCohort 2 And 3: Absolute Change From Baseline in Sweat Chloride at Day 14
Time frame:
Cohort 2: Baseline, Day 14
Reported as:
Least squares mean · mmol/L
Cohort 2 And 3: Absolute Change From Baseline in Sweat Chloride at Day 14
mmol/LCohort 2: LUM 200 mg qd - Period 1Cohort 2: LUM 400 mg qd - Period 1Cohort 2: LUM 600 mg qd (HO) - Period 1Cohort 2: LUM 600 mg qd (HE) - Period 1Cohort 3: LUM 400 mg q12h - Period 1Cohort 2 and 3: Placebo (HO and HE) - Period 1
Cohort 2 And 3: Absolute Change From Baseline in Sweat Chloride at Day 14-6.490 (-11.226 to -1.755)-5.901 (-10.910 to -0.892)-9.442 (-13.953 to -4.931)-3.137 (-8.167 to 1.893)-9.179 (-15.470 to -2.888)0.048 (-4.162 to 4.258)
SecondaryCohort 4: Absolute Change From Baseline in Sweat Chloride at Day 56
Time frame:
Cohort 4: Baseline, Day 56
Reported as:
Least squares mean · mmol/L
Cohort 4: Absolute Change From Baseline in Sweat Chloride at Day 56
mmol/LCohort 4: PlaceboCohort 4: LUM 400 mg q12h+IVA 250 mg q12h
Cohort 4: Absolute Change From Baseline in Sweat Chloride at Day 56-0.78 ± 1.230-11.82 ± 1.281
SecondaryCohort 1: Absolute Change From Day 14 in FEV1 at Day 21

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

Time frame:
Cohort 1: Day 14, Day 21
Reported as:
Least squares mean · liters
Cohort 1: Absolute Change From Day 14 in FEV1 at Day 21
litersCohort 1: LUM 200 mg qd+IVA 150 mg q12h - Period 2Cohort 1: LUM 200 mg qd+IVA 250 mg q12h - Period 2Cohort 1: Placebo - Period 2
Cohort 1: Absolute Change From Day 14 in FEV1 at Day 210.128 (0.030 to 0.225)0.015 (-0.094 to 0.124)-0.046 (-0.138 to 0.047)
SecondaryCohort 1: Absolute Change From Day 14 in ppFEV1 at Day 21

FEV1 and ppFEV1 are defined in Outcome Measure 6.

Time frame:
Cohort 1: Day 14, Day 21
Reported as:
Least squares mean · percent predicted of FEV1
Cohort 1: Absolute Change From Day 14 in ppFEV1 at Day 21
percent predicted of FEV1Cohort 1: LUM 200 mg qd+IVA 150 mg q12h - Period 2Cohort 1: LUM 200 mg qd+IVA 250 mg q12h - Period 2Cohort 1: Placebo - Period 2
Cohort 1: Absolute Change From Day 14 in ppFEV1 at Day 213.46 (0.87 to 6.05)0.63 (-2.20 to 3.46)-1.44 (-3.89 to 1.01)
SecondaryCohort 2 and 3: Absolute Change From Day 28 in ppFEV1 at Day 56

FEV1 and ppFEV1 are defined in Outcome Measure 6.

Time frame:
Cohort 2 and 3: Day 28, Day 56
Reported as:
Least squares mean · percent predicted of FEV1
Cohort 2 and 3: Absolute Change From Day 28 in ppFEV1 at Day 56
percent predicted of FEV1Cohort 2: LUM 200 mg qd+IVA 250 mg q12h (HO) - Period 2Cohort 2: LUM 400 mg qd+IVA 250 mg q12h (HO) - Period 2Cohort 2: LUM 600 mg qd+IVA 250 mg q12h (HO) - Period 2Cohort 2: LUM 600 mg qd+IVA 250 mg q12h (HE) - Period 2Cohort 3: LUM 400 mg q12h+IVA 250 mg q12h (HO) - Period 2Cohort 2 and 3: Placebo (HO and HE) - Period 2
Cohort 2 and 3: Absolute Change From Day 28 in ppFEV1 at Day 561.96 (-0.84 to 4.76)1.99 (-0.87 to 4.84)6.15 (3.27 to 9.02)2.29 (-0.82 to 5.39)6.09 (2.02 to 10.16)-1.57 (-4.24 to 1.09)
SecondaryCohort 2 and 3: Relative Change From Day 28 in ppFEV1 at Day 56

FEV1 and ppFEV1 are defined in Outcome Measure 6.

Time frame:
Cohort 2 and 3: Day 28, Day 56
Reported as:
Least squares mean · percent change
Cohort 2 and 3: Relative Change From Day 28 in ppFEV1 at Day 56
percent changeCohort 2: LUM 200 mg qd+IVA 250 mg q12h (HO) - Period 2Cohort 2: LUM 400 mg qd+IVA 250 mg q12h (HO) - Period 2Cohort 2: LUM 600 mg qd+IVA 250 mg q12h (HO) - Period 2Cohort 2: LUM 600 mg qd+IVA 250 mg q12h (HE) - Period 2Cohort 3: LUM 400 mg q12h+IVA 250 mg q12h (HO) - Period 2Cohort 2 and 3: Placebo (HO and HE) - Period 2
Cohort 2 and 3: Relative Change From Day 28 in ppFEV1 at Day 563.13 (-1.29 to 7.54)2.98 (-1.52 to 7.48)9.70 (5.17 to 14.23)4.30 (-0.59 to 9.19)8.24 (1.83 to 14.65)-2.05 (-6.25 to 2.15)
SecondaryCohort 2 and 3: Absolute Change From Baseline in ppFEV1 at Day 28 and 56

FEV1 and ppFEV1 are defined in Outcome Measure 6.

Time frame:
Cohort 2 and 3: Baseline, Day 28 and 56
Reported as:
Least squares mean · percent predicted of FEV1
Cohort 2 and 3: Absolute Change From Baseline in ppFEV1 at Day 28 and 56
percent predicted of FEV1Cohort 2: LUM 200 mg qd/LUM 200 mg qd+IVA 250 mg q12h (HO)Cohort 2: LUM 400 mg qd/LUM 400 mg qd+IVA 250 mg q12h (HO)Cohort 2: LUM 600 mg qd/LUM 600 mg qd+IVA 250 mg q12h (HO)Cohort 2: LUM 600 mg qd/LUM 600 mg qd+IVA 250 mg q12h (HE)Cohort 3: LUM 400 mg q12h/LUM 400 mg q12h+IVA 250 mg q12h (HO)Cohort 2 and 3: Placebo (HO and HE)
Day 28: (n= 21, 20, 20, 18, 11, 27)0.21 (-2.77 to 3.19)-1.35 (-4.39 to 1.69)-2.62 (-5.67 to 0.42)-3.82 (-7.03 to -0.61)-4.52 (-8.65 to -0.39)-0.03 (-2.68 to 2.62)
Day 56: (n= 21, 20, 20, 17, 10, 24)1.82 (-1.28 to 4.91)0.64 (-2.52 to 3.80)3.59 (0.41 to 6.77)-1.68 (-5.12 to 1.75)2.16 (-2.34 to 6.66)-2.02 (-4.97 to 0.93)
SecondaryCohort 2 and 3: Relative Change From Baseline in FEV1 at Day 28 and 56

FEV1 and ppFEV1 are defined in Outcome Measure 6.

Time frame:
Cohort 2 and 3: Baseline, Day 28 and 56
Reported as:
Least squares mean · percent change
Cohort 2 and 3: Relative Change From Baseline in FEV1 at Day 28 and 56
percent changeCohort 2: LUM 200 mg qd/LUM 200 mg qd+IVA 250 mg q12h (HO)Cohort 2: LUM 400 mg qd/LUM 400 mg qd+IVA 250 mg q12h (HO)Cohort 2: LUM 600 mg qd/LUM 600 mg qd+IVA 250 mg q12h (HO)Cohort 2: LUM 600 mg qd/LUM 600 mg qd+IVA 250 mg q12h (HE)Cohort 3: LUM 400 mg q12h/LUM 400 mg q12h+IVA 250 mg q12h (HO)Cohort 2 and 3: Placebo (HO and HE)
Day 28: (n= 21, 20, 20, 18, 11, 27)0.24 (-4.27 to 4.75)-1.15 (-5.75 to 3.45)-3.13 (-7.74 to 1.48)-5.46 (-10.32 to -0.60)-6.39 (-12.65 to -0.14)1.89 (-2.12 to 5.90)
Day 56: (n= 21, 20, 20, 17, 10, 24)2.51 (-2.21 to 7.23)1.72 (-3.09 to 6.53)5.55 (0.70 to 10.39)-2.34 (-7.57 to 2.89)2.96 (-3.90 to 9.81)-2.42 (-6.91 to 2.08)
SecondaryCohort 4: Relative Change From Baseline in Percent Predicted FEV1 at Day 56

FEV1 and ppFEV1 are defined in Outcome Measure 6.

Time frame:
Cohort 4: Baseline, Day 56
Reported as:
Least squares mean · percent change
Cohort 4: Relative Change From Baseline in Percent Predicted FEV1 at Day 56
percent changeCohort 4: PlaceboCohort 4: LUM 400 mg q12h+IVA 250 mg q12h
Cohort 4: Relative Change From Baseline in Percent Predicted FEV1 at Day 56-2.20 ± 1.373-0.69 ± 1.423
SecondaryCohort 2 and 3: Absolute Change From Day 28 in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score at Day 56

The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for subjects with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.

Time frame:
Cohort 2 and 3: Day 28, Day 56
Reported as:
Least squares mean · units on a scale
Cohort 2 and 3: Absolute Change From Day 28 in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score at Day 56
units on a scaleCohort 2: LUM 200 mg qd+IVA 250 mg q12h (HO) - Period 2Cohort 2: LUM 400 mg qd+IVA 250 mg q12h (HO) - Period 2Cohort 2: LUM 600 mg qd+IVA 250 mg q12h (HO) - Period 2Cohort 2: LUM 600 mg qd+IVA 250 mg q12h (HE) - Period 2Cohort 3: LUM 400 mg q12h+IVA 250 mg q12h (HO) - Period 2Cohort 2 and 3: Placebo (HO and HE) - Period 2
Cohort 2 and 3: Absolute Change From Day 28 in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score at Day 563.3 (-3.6 to 10.1)7.9 (0.8 to 14.9)8.9 (1.9 to 15.9)5.5 (-2.1 to 13.1)11.2 (1.3 to 21.1)-8.6 (-14.9 to -2.2)
SecondaryCohort 4: Absolute Change From Baseline in CFQ-R Respiratory Domain Score at Day 56

CFQ-R respiratory domain is defined in Outcome Measure 17.

Time frame:
Cohort 4: Baseline, Day 56
Reported as:
Least squares mean · units on a scale
Cohort 4: Absolute Change From Baseline in CFQ-R Respiratory Domain Score at Day 56
units on a scaleCohort 4: PlaceboCohort 4: LUM 400 mg q12h+IVA 250 mg q12h
Cohort 4: Absolute Change From Baseline in CFQ-R Respiratory Domain Score at Day 56-0.82 ± 1.8025.66 ± 1.864
SecondaryCohort 4: Absolute Change From Baseline in Body Mass Index (BMI) at Day 56

BMI was defined as weight in kilogram (kg) divided by height\*height in square meter (m\^2).

Time frame:
Cohort 4: Baseline, Day 56
Reported as:
Least squares mean · kg/m^2
Cohort 4: Absolute Change From Baseline in Body Mass Index (BMI) at Day 56
kg/m^2Cohort 4: PlaceboCohort 4: LUM 400 mg q12h+IVA 250 mg q12h
Cohort 4: Absolute Change From Baseline in Body Mass Index (BMI) at Day 560.08 ± 0.075-0.04 ± 0.077
SecondaryCohort 4: Absolute Change From Baseline in Weight at Day 56
Time frame:
Cohort 4: Baseline, Day 56
Reported as:
Least squares mean · kg
Cohort 4: Absolute Change From Baseline in Weight at Day 56
kgCohort 4: PlaceboCohort 4: LUM 400 mg q12h+IVA 250 mg q12h
Cohort 4: Absolute Change From Baseline in Weight at Day 560.16 ± 0.211-0.11 ± 0.216

Adverse events

Collected over Cohort 1: Day 1 up to 28 days after last dose (Last dose = Day 21); Cohort 2 and 3: Day 1 up to 28 days after last dose (Last dose = Day 56); Cohort 4: Day 1 up to 28 days after last dose (Last dose = Day 56). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: LUM 200 mg qd - Period 1—0/41 (0%)29/41 (70.7%)
Cohort 1: LUM 200 mg qd+IVA 150 mg q12h - Period 2—0/20 (0%)14/20 (70%)
Cohort 1: LUM 200 mg qd+IVA 250 mg q12h - Period 2—0/20 (0%)12/20 (60%)
Cohort 1: Placebo - Period 1—0/21 (0%)12/21 (57.1%)
Cohort 1: Placebo - Period 2—0/21 (0%)15/21 (71.4%)
Cohort 2: LUM 200 mg qd - Period 1—2/23 (8.7%)17/23 (73.9%)
Cohort 2: LUM 400 mg qd - Period 1—0/21 (0%)18/21 (85.7%)
Cohort 2: LUM 600 mg qd - Period 1—3/42 (7.1%)37/42 (88.1%)
Cohort 3: LUM 400 mg q12h - Period 1—2/11 (18.2%)6/11 (54.5%)
Cohort 2 and 3: Placebo (HO and HE) - Period 1—1/27 (3.7%)23/27 (85.2%)
Cohort 2: LUM 200 mg qd+IVA 250 mg q12h (HO) - Period 2—0/21 (0%)12/21 (57.1%)
Cohort 2: LUM 400 mg qd+IVA 250 mg q12h (HO) - Period 2—1/20 (5%)15/20 (75%)
Cohort 2: LUM 600 mg qd+IVA 250 mg q12h (HO&HE) - Period 2—4/38 (10.5%)26/38 (68.4%)
Cohort 3: LUM 400 mg q12h+IVA 250 mg q12h (HO) - Period 2—1/11 (9.1%)10/11 (90.9%)
Cohort 2 and 3: Placebo (HO and HE) - Period 2—4/27 (14.8%)20/27 (74.1%)
Cohort 4: Placebo—5/63 (7.9%)53/63 (84.1%)
Cohort 4: LUM 400 mg q12h+IVA 250 mg q12h—9/62 (14.5%)51/62 (82.3%)
Most frequent serious events
Most frequent serious events
EventCohort 1: LUM 200 mg qd - Period 1Cohort 1: LUM 200 mg qd+IVA 150 mg q12h - Period 2Cohort 1: LUM 200 mg qd+IVA 250 mg q12h - Period 2Cohort 1: Placebo - Period 1Cohort 1: Placebo - Period 2Cohort 2: LUM 200 mg qd - Period 1Cohort 2: LUM 400 mg qd - Period 1Cohort 2: LUM 600 mg qd - Period 1Cohort 3: LUM 400 mg q12h - Period 1Cohort 2 and 3: Placebo (HO and HE) - Period 1Cohort 2: LUM 200 mg qd+IVA 250 mg q12h (HO) - Period 2Cohort 2: LUM 400 mg qd+IVA 250 mg q12h (HO) - Period 2Cohort 2: LUM 600 mg qd+IVA 250 mg q12h (HO&HE) - Period 2Cohort 3: LUM 400 mg q12h+IVA 250 mg q12h (HO) - Period 2Cohort 2 and 3: Placebo (HO and HE) - Period 2Cohort 4: PlaceboCohort 4: LUM 400 mg q12h+IVA 250 mg q12h
CYSTIC FIBROSIS LUNGCongenital, familial and genetic disorders0/410/200/200/210/211/230/211/421/111/270/211/203/381/114/270/630/62
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations0/410/200/200/210/210/230/210/420/110/270/210/200/380/110/273/637/62
DYSPNOEARespiratory, thoracic and mediastinal disorders0/410/200/200/210/210/230/211/420/110/270/210/200/381/110/270/630/62
RESPIRATION ABNORMALRespiratory, thoracic and mediastinal disorders0/410/200/200/210/210/230/210/421/110/270/210/200/380/110/270/630/62
HYPERSENSITIVITYImmune system disorders0/410/200/200/210/211/230/210/420/110/270/210/200/380/110/270/630/62
HaemoptysisRespiratory, thoracic and mediastinal disorders0/410/200/200/210/210/230/210/420/110/270/210/201/380/111/271/631/62
NephrolithiasisRenal and urinary disorders0/410/200/200/210/210/230/210/420/110/270/210/200/380/111/271/630/62
BLOOD CREATINE PHOSPHOKINASE INCREASEDInvestigations0/410/200/200/210/210/230/210/420/110/270/210/201/380/110/270/630/62
PNEUMONIAInfections and infestations0/410/200/200/210/210/230/211/420/110/270/210/200/380/110/270/630/62
Spirometry abnormalInvestigations0/410/200/200/210/210/230/210/420/110/270/210/200/380/110/270/631/62
Most frequent other events
Showing 10 of 264
Most frequent other events
EventCohort 1: LUM 200 mg qd - Period 1Cohort 1: LUM 200 mg qd+IVA 150 mg q12h - Period 2Cohort 1: LUM 200 mg qd+IVA 250 mg q12h - Period 2Cohort 1: Placebo - Period 1Cohort 1: Placebo - Period 2Cohort 2: LUM 200 mg qd - Period 1Cohort 2: LUM 400 mg qd - Period 1Cohort 2: LUM 600 mg qd - Period 1Cohort 3: LUM 400 mg q12h - Period 1Cohort 2 and 3: Placebo (HO and HE) - Period 1Cohort 2: LUM 200 mg qd+IVA 250 mg q12h (HO) - Period 2Cohort 2: LUM 400 mg qd+IVA 250 mg q12h (HO) - Period 2Cohort 2: LUM 600 mg qd+IVA 250 mg q12h (HO&HE) - Period 2Cohort 3: LUM 400 mg q12h+IVA 250 mg q12h (HO) - Period 2Cohort 2 and 3: Placebo (HO and HE) - Period 2Cohort 4: PlaceboCohort 4: LUM 400 mg q12h+IVA 250 mg q12h
COUGHRespiratory, thoracic and mediastinal disorders6/414/201/201/214/213/238/2112/421/116/273/215/205/383/116/2712/6313/62
RESPIRATION ABNORMALRespiratory, thoracic and mediastinal disorders1/410/201/201/211/210/232/217/422/110/271/210/202/380/110/279/6317/62
DYSPNOEARespiratory, thoracic and mediastinal disorders3/410/200/201/210/210/231/2110/420/110/270/210/201/380/110/274/639/62
HEADACHENervous system disorders4/410/201/204/215/211/234/214/421/115/270/212/207/382/115/2711/633/62
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations0/412/200/200/210/215/231/212/420/110/273/212/203/381/114/273/633/62
OROPHARYNGEAL PAINRespiratory, thoracic and mediastinal disorders2/411/202/200/212/212/230/211/421/111/271/214/200/382/111/275/633/62
SPUTUM INCREASEDRespiratory, thoracic and mediastinal disorders0/410/200/200/210/210/230/210/420/110/270/210/200/380/110/2712/6310/62
NAUSEAGastrointestinal disorders2/410/201/200/210/210/231/218/421/113/270/211/203/380/112/277/637/62
PRODUCTIVE COUGHRespiratory, thoracic and mediastinal disorders3/411/200/202/213/212/232/216/422/115/272/211/201/382/111/273/633/62
SINUS CONGESTIONRespiratory, thoracic and mediastinal disorders0/410/200/200/211/211/230/213/420/112/270/211/200/382/112/274/630/62

Baseline characteristics

Full Analysis Set (FAS) for Cohort 1, 2, and 3 included all randomized participants who received at least 1 dose of study drug and FAS for Cohort 4 included all randomized participants who received any amount of study drug.

Age, Categorical
Age, Categorical(Participants)Cohort 1: PlaceboCohort 1: LUM 200 mg qd/LUM 200 mg qd+IVA 150 mg q12hCohort 1: LUM 200 mg qd/LUM 200 mg qd+IVA 250 mg q12hCohort 2 and 3: Placebo (HO and HE)Cohort 2: LUM 200 mg qd/LUM 200 mg qd+IVA 250 mg q12h (HO)Cohort 2: LUM 400 mg qd/LUM 400 mg qd+IVA 250 mg q12h (HO)Cohort 2: LUM 600 mg qd/LUM 600 mg qd+IVA 250 mg q12h (HO&HE)Cohort 3: LUM 400 mg q12h/LUM 400 mg q12h+IVA 250 mg q12h (HO)Cohort 4: PlaceboCohort 4: LUM 400 mg q12h+IVA 250 mg q12hTotal
<=18 years00000000000
Between 18 and 65 years21202127232142116362311
>=65 years00000000000
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: PlaceboCohort 1: LUM 200 mg qd/LUM 200 mg qd+IVA 150 mg q12hCohort 1: LUM 200 mg qd/LUM 200 mg qd+IVA 250 mg q12hCohort 2 and 3: Placebo (HO and HE)Cohort 2: LUM 200 mg qd/LUM 200 mg qd+IVA 250 mg q12h (HO)Cohort 2: LUM 400 mg qd/LUM 400 mg qd+IVA 250 mg q12h (HO)Cohort 2: LUM 600 mg qd/LUM 600 mg qd+IVA 250 mg q12h (HO&HE)Cohort 3: LUM 400 mg q12h/LUM 400 mg q12h+IVA 250 mg q12h (HO)Cohort 4: PlaceboCohort 4: LUM 400 mg q12h+IVA 250 mg q12hTotal
Female1081391191953129144
Male111281812122363233167
08

Study locations

56 sites
  • Birmingham, Alabama, United States
  • Anchorage, Alaska, United States
  • La Jolla, California, United States
  • Long Beach, California, United States
  • Palo Alto, California, United States
  • Sacramento, California, United States
  • Denver, Colorado, United States
  • New Haven, Connecticut, United States
  • Miami, Florida, United States
  • Orlando, Florida, United States
  • Tampa, Florida, United States
  • Atlanta, Georgia, United States
  • Boise, Idaho, United States
  • Chicago, Illinois, United States
  • Iowa City, Iowa, United States
  • Kansas City, Kansas, United States
  • Lexington, Kentucky, United States
  • New Orleans, Louisiana, United States
  • Baltimore, Maryland, United States
  • Boston, Massachusetts, United States
  • Minneapolis, Minnesota, United States
  • St. Louis, Missouri, United States
  • Omaha, Nebraska, United States
  • Lebanon, New Hampshire, United States
  • Buffalo, New York, United States
  • New Hyde Park, New York, United States
  • New York, New York, United States
  • Rochester, New York, United States
  • Syracuse, New York, United States
  • Chapel Hill, North Carolina, United States
  • Akron, Ohio, United States
  • Cleveland, Ohio, United States
  • Columbus, Ohio, United States
  • Oklahoma City, Oklahoma, United States
  • Philadelphia, Pennsylvania, United States
  • Pittsburgh, Pennsylvania, United States
  • Pittsburg, Pennsylvania, United States
  • Charleston, South Carolina, United States
  • Sioux Falls, South Dakota, United States
  • Adelaide, Australia
  • Brisbane, Australia
  • Chermside, Australia
  • Nedlands, Australia
  • Parkville Victoria, Australia
  • Westmead, Australia
  • Leuven, Belgium
  • Pierre Benite Cedex, Rhone, France
  • Paris, France
  • Jena, Thueringen, Germany
  • Berlin, Germany
  • Bochum, Germany
  • Essen, Germany
  • Koeln, Germany
  • Auckland, New Zealand
  • Christchurch, New Zealand
  • London, United Kingdom
09

References and documents

Publications

  • Southern KW, Murphy J, Sinha IP, Nevitt SJ. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del). Cochrane Database Syst Rev. 2020 Dec 17;12(12):CD010966. doi: 10.1002/14651858.CD010966.pub3. PubMed 33331662 ↗
  • Rowe SM, McColley SA, Rietschel E, Li X, Bell SC, Konstan MW, Marigowda G, Waltz D, Boyle MP; VX09-809-102 Study Group. Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR. Ann Am Thorac Soc. 2017 Feb;14(2):213-219. doi: 10.1513/AnnalsATS.201609-689OC. PubMed 27898234 ↗
  • Boyle MP, Bell SC, Konstan MW, McColley SA, Rowe SM, Rietschel E, Huang X, Waltz D, Patel NR, Rodman D; VX09-809-102 study group. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med. 2014 Jul;2(7):527-38. doi: 10.1016/S2213-2600(14)70132-8. Epub 2014 Jun 24. PubMed 24973281 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2010, a primary completion of Apr 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2015, 1 year 6 months after primary completion. A results delay was requested in May 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2010
First posted
Oct 20, 2010
Start
Oct 2010
Primary completionActual
Apr 2014
CompletionActual
Apr 2014
Results delay requested
May 8, 2015
Results first posted
Oct 5, 2015
Last update
Oct 5, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 5, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01225211
Responsible party
Sponsor
First posted
Oct 20, 2010
Start date
Oct 2010
Primary completion
Apr 2014
Completion
Apr 2014
Results posted
Oct 5, 2015
Last update
Oct 5, 2015

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lumacaftor · Ivacaftor

Start the discussion